Highest-materiality recent filing
Cartesian secures up to $150M debt facility; CMO resigns; Phase 3 data expected Q1 2027
Secured up to $150M credit facility with K2 HealthVentures; initial $50M tranche funded at close on May 22, 2026.
Cartesian Q1 net loss $39.2M ($1.46/sh) vs $17.7M; cash $120.4M; pipeline advances
Net loss widened to $39.2M from $17.7M YoY; higher R&D spend on Phase 3 AURORA trial.
Cartesian Therapeutics reports FY2025 net loss of $130.3M; cash $126.9M funds into mid-2027
Net loss of $130.3M ($5.02 per basic share) compared to $77.4M ($4.48) in FY2024.
Cartesian updates Descartes-08 pipeline; IND accepted in myositis, pediatric trial initiated
Phase 3 AURORA trial for Descartes-08 in myasthenia gravis enrollment on track; data expected to support cash runway into mid-2027.
Cartesian Therapeutics appoints Adrian Bot to board; brings CAR T and RNA therapy expertise
Appointed Adrian Bot, M.D., Ph.D., as Class II director effective Dec 16, 2025; will serve on Science and Technology Committee.
Cartesian reports 100% LLDAS response in Phase 2 SLE; expands Descartes-08 into myositis
100% LLDAS response at Month 3 (n=3) in Phase 2 SLE trial; 2 of 3 achieved DORIS remission.
Cartesian Q3 net loss $35.9M; cash $145.1M; AURORA trial on track
Net loss of $35.9M ($1.38/share) vs $24.2M ($1.13/share) in Q3 2024.
Cartesian Therapeutics eliminates CSO role, terminates Dr. Christopher Jewell effective Nov 14, 2025
CSO position eliminated; Dr. Christopher Jewell terminated without cause effective November 14, 2025.
Cash, equivalents and restricted cash $162.1M as of June 30, 2025; expected to fund operations into mid-2027.
Cartesian reports Descartes-08 Phase 2b MG data: sustained 12-month benefit, Phase 3 on track
Average MG-ADL reduction of 4.8 points at Month 12; 83% maintained clinically meaningful response.
Cartesian Therapeutics FY2024 net loss $77.4M; cash $214.3M; Phase 3 MG trial on track
Net loss of $77.4M ($4.48 loss per share) vs $219.7M loss in FY2023; R&D expenses $45.1M.
On May 22, 2026, Milos Miljkovic, M.D., the Company’s Chief Medical Officer, delivered a notice of resignation to the Company.
Dr. Kurtoglu’s employment with the Company will end effective May 1, 2025
Max materiality 0.85 · Median 0.60 · Most common event leadership